Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

NCT04905810 PHASE2 RECRUITING

This phase II trial evaluates the effect of azacitidine or decitabine and venetoclax in treating patients with acute myeloid leukemia that has not been treated before (treatment naive) or has come back (relapsed). Chemotherapy drugs, such as azacitidine, decitabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Details

Lead sponsor	Brian Jonas
Phase	PHASE2
Status	RECRUITING
Enrolment	20
Start date	Wed Feb 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Dec 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Acute Myeloid Leukemia
• Recurrent Acute Myeloid Leukemia

Interventions

• Azacitidine
• Decitabine
• Venetoclax

Countries

United States